ArticleBMC microbiology2026
Effects of phage-based treatments against an OXA-48-producing Klebsiella pneumoniae isolate in simulated human gut microbiomes.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCarbapenem-resistant K. pneumoniae (CRKP) is one of the most prevalent antimicrobial-resistant pathogens, primarily causing nosocomial infections. These bacteria often colonize the gut microbiota, and their carriage is an important risk factor for later infection. Phages are an emerging alternative against antimicrobial-resistant bacteria causing infections, but their effect on the microbiota is still poorly understood.
resultsHere, we simulated the colonization of the gut microbiota of three healthy adults by an OXA-48-producing CRKP isolate in a dynamic in vitro colonic simulator (SHIME®) and evaluated the effect of phage treatments in reducing CRKP load. Phage growth dynamics in the system seemed to be dependent on phage host range, rather than the donor’s microbiota composition. Additionally, phage treatment significantly reduced K. pneumoniae load and blaOXA-48 copy number, highlighting its potential for controlling the CRKP population. Importantly, phage treatment did not affect the microbiota diversity of any of the three donors, suggesting it has a minimal impact on the microbiome.
conclusionsOur results support the potential of phage-based strategies for the biocontrol of CRKP in the gut microbiota, reducing the abundance of this pathogen in its main reservoirs and preventing nosocomial CRKP infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.